Genmab
Genmab is a biotechnology company based in Copenhagen that specializes in the development of fully human antibody therapeutics aimed at treating cancer and other serious diseases. The company employs advanced proprietary technologies, including DuoBody, HexaBody, DuoHexaBody, and HexElect, to create innovative therapies designed to meet unmet medical needs. Genmab's leading product, Darzalex, developed in partnership with Johnson & Johnson, is recognized as the standard treatment for multiple myeloma. In addition to Darzalex, the company's portfolio includes Tepezza for thyroid eye disease, Kesimpta for relapsing multiple sclerosis, Rybrevant for non-small cell lung cancer, Tivdak for cervical cancer, and Epkinly, all of which are developed in collaboration with various pharmaceutical partners. Through its commitment to research and development, Genmab aims to deliver transformative therapies that improve patient outcomes.
ProfoundBio
Acquisition in 2024
ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.
Bolt Biotherapeutics
Post in 2021
Bolt Biotherapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. The company employs its proprietary Boltbody platform, which features immune-stimulating antibody conjugates (ISAC) that link tumor-targeting antibodies with powerful immune stimulants. This approach aims to activate the immune system against tumors, effectively transforming cold tumors into immunologically active ones. Bolt Biotherapeutics is advancing several candidates in its pipeline, including BDC-1001, a monotherapy targeting HER2-expressing solid tumors, and BDC-3042, among others. Founded in 2015 and headquartered in Redwood City, California, the company leverages its expertise in myeloid biology and cancer drug development to create targeted therapies that harness both innate and adaptive immune responses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.